GLP-1 drugs like semaglutide, tirzepatide, and liraglutide mainly cause GI symptoms, nausea, vomiting, diarrhea, constipation, bloating, and can rarely lead to pancreatitis, gallbladder disease, or kidney issues
Brandt SJ, Mller TD, DiMarchi RD, et al
Several trials have demonstrated that GLP-1 RAs reduce cardiovascular risk in patients with type 2 diabetes mellitus and ASCVD or high cardiovascular risk and have beneficial effects on cardio-renal outcomes beyond their blood glucose-lowering effects in type 2 diabetes mellitus patients
Depending on the patients response and tolerance, the dose may be further increased every four weeks, typically progressing to 7.5 mg, 10 mg, 12.5 mg, and up to a maximum of 15 mg once weekly
Conditions That May Benefit from B12 Injections Celiac disease Celiac patients may have micronutrient deficiencies, one of which includes Vitamin B12
Invitrogen) and kept in the dark for 1 h at RT